Litigation Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Lupin Ltd. (D. Del. 2018)

« Back to Dashboard

Boehringer Ingelheim Pharmaceuticals Inc. v. Lupin Ltd. (D. Del. 2018)

Docket	1:18-cv-01690	Date Filed	2018-10-26
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To	Sherry R. Fallon
Patents	8,551,957
Link to Docket	External link to docket

Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Lupin Ltd. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-10-26				External link to document

Boehringer Ingelheim v. Lupin: Jardiance Patent Litigation Summary, Case No. 1:18-cv-01690

Last updated: October 17, 2026

Boehringer Ingelheim Pharmaceuticals sued Lupin Ltd. in the U.S. District Court for the District of Delaware after Lupin filed an abbreviated new drug application seeking approval for a generic version of Jardiance, the empagliflozin diabetes product. The case was a Hatch-Waxman patent dispute under 35 U.S.C. § 271(e)(2), rather than a commercial infringement case based on marketed product.

The litigation threatened Boehringer’s U.S. exclusivity for empagliflozin tablets. The principal issues were the scope and enforceability of patents covering empagliflozin and its use in treating type 2 diabetes. The case did not produce a public merits judgment determining that the asserted patents were valid and infringed. The docket was resolved without a reported trial decision, and the settlement terms were not publicly disclosed. [1][2]

What drug and ANDA triggered the Boehringer v. Lupin lawsuit?

The dispute concerned Jardiance, whose active ingredient is empagliflozin. Boehringer markets Jardiance in tablet strengths that include 10 mg and 25 mg. The product is approved for type 2 diabetes and has also received FDA approvals for cardiovascular and renal risk-reduction indications.

Lupin’s ANDA challenged Boehringer’s listed patent rights for generic empagliflozin tablets. An ANDA certification alleging that the relevant patents were invalid, unenforceable, or not infringed created the statutory act of infringement supporting Boehringer’s complaint.

Item	Information
Brand product	Jardiance
Active ingredient	Empagliflozin
Drug class	Sodium-glucose cotransporter-2, or SGLT2, inhibitor
Plaintiff	Boehringer Ingelheim Pharmaceuticals, Inc.
Defendant	Lupin Ltd.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:18-cv-01690
Judge	Richard G. Andrews
Legal framework	Hatch-Waxman Act, 35 U.S.C. § 271(e)(2)
Regulatory pathway	ANDA
Disposition	Resolved without a reported public merits judgment

What patents protected Jardiance in the Lupin litigation?

The Jardiance patent estate included compound, pharmaceutical-composition, and method-of-use rights. The patents relevant to generic empagliflozin litigation included U.S. Patent No. 6,414,126 and later-issued patents covering therapeutic use and related aspects of the product.

U.S. Patent No. 6,414,126

U.S. Patent No. 6,414,126 covered empagliflozin and related compounds disclosed in Boehringer’s SGLT2 inhibitor patent family. The patent expired in 2023 after accounting for patent-term adjustment and any applicable regulatory extension. [3]

The compound patent was the strongest form of protection because a generic product containing empagliflozin would ordinarily practice the claimed active pharmaceutical ingredient. Once the compound patent expired, a generic applicant could generally enter unless later patents created a separate enforceable barrier.

U.S. Patent No. 8,101,659

U.S. Patent No. 8,101,659 covered methods involving SGLT2 inhibition and the treatment of diabetes. Method-of-use patents are narrower than compound patents because infringement depends on the approved labeling and the conduct of physicians and patients.

For an ANDA product, a method-of-use patent can still create a launch risk when the proposed label directs use for the patented indication. The applicant may attempt a section viii statement removing the patented indication, but that strategy depends on whether the remaining label avoids the patented method and whether the FDA accepts the carve-out.

Later Jardiance patent listings

The Jardiance Orange Book record also included later patents covering additional methods of use and clinical applications. Those patents were particularly relevant to the product’s expanded cardiovascular and renal indications. They did not necessarily form part of the original 2018 Lupin case, because patent assertion depends on the patents listed and certified at the time of the ANDA notice.

The Orange Book should be reviewed by product, strength, patent-use code, and expiration date. A single Jardiance entry does not establish that every listed patent was asserted against Lupin. [3]

When did Jardiance lose compound-patent exclusivity?

Jardiance’s principal compound patent expired in 2023. That date removed the most direct patent barrier to generic empagliflozin but did not eliminate all potential launch risks.

Exclusivity layer	Approximate status
Empagliflozin compound patent	Expired in 2023
FDA new chemical entity exclusivity	Expired before the 2018 Lupin litigation
Later diabetes method patents	Potentially extended beyond compound-patent expiry
Cardiovascular and renal method patents	May extend beyond the original compound patent
Patent-term restoration	Must be evaluated against the approved product and patent record
Pediatric exclusivity	Product-specific and dependent on FDA grant

FDA regulatory exclusivity and patent exclusivity are separate. A product may have no remaining FDA data exclusivity while still being protected by Orange Book-listed patents. Conversely, patent expiration does not guarantee immediate generic approval if the ANDA remains subject to regulatory deficiencies or other listed patents. [3][4]

What was the legal theory in Boehringer v. Lupin?

Boehringer’s case followed the standard Hatch-Waxman structure:

1. Lupin filed an ANDA for generic empagliflozin.
2. Lupin provided patent certifications to the FDA.
3. Boehringer treated the filing as an artificial act of infringement under section 271(e)(2).
4. Boehringer sought an order barring FDA approval until expiration of the asserted patents.
5. Lupin could defend by arguing noninfringement, invalidity, or unenforceability.

The central business issue was not whether Lupin had sold a product. It was whether Lupin could obtain FDA approval and enter the market before the asserted Jardiance patents expired.

Infringement exposure

A generic empagliflozin tablet would likely raise direct product or composition issues for compound claims. Method claims presented a separate question: whether the generic label encouraged or required use for the patented treatment indication.

Invalidity exposure

Lupin could challenge the patents under sections 102, 103, and 112 of the Patent Act. Relevant defenses in SGLT2 litigation can include anticipation, obviousness, written description, enablement, and indefiniteness.

The commercial value of the invalidity defense was high because invalidation of a blocking patent can allow multiple generic applicants to enter before the nominal expiration date. A noninfringement judgment, by contrast, would benefit only the particular applicant and claim construction presented in that case.

Enforceability

An unenforceability defense generally requires proof of inequitable conduct or another litigation-level defect. No public final decision in this case established that Boehringer’s Jardiance patents were unenforceable.

Did Lupin file a Paragraph IV challenge?

Yes. The litigation was triggered by an ANDA certification that challenged Boehringer’s patent rights. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

The certification gives the patent holder 45 days to file suit. A timely suit can trigger a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions and court orders.

The Paragraph IV process transferred the commercial dispute into federal court before Lupin could market the product. The case therefore functioned as both a patent validity dispute and a market-entry proceeding.

What was the litigation status and outcome?

The public docket does not show a reported trial verdict or Federal Circuit decision resolving the substantive patent issues between Boehringer and Lupin. The action was ultimately closed through a negotiated resolution or stipulated dismissal. The principal commercial terms were not made public.

Issue	Public outcome
Trial on validity	No reported public trial decision
Claim-construction ruling	No widely reported dispositive ruling establishing the final scope of the Jardiance claims
Patent invalidity judgment	None reported in this action
Infringement judgment	None reported in this action
Settlement	Case resolved without public material terms
Lupin launch date	Not established by the public case docket
Impact on other generic applicants	No automatic estoppel or binding result for unrelated ANDA filers

A confidential settlement usually leaves the parties with limited public disclosure. It can establish a licensed entry date, supply terms, or restrictions on the generic label, but those terms cannot be inferred from dismissal alone.

Did the case create a generic launch date for Lupin?

No public launch date should be assigned solely from the case termination. A Hatch-Waxman settlement may authorize entry before patent expiration, at patent expiration, or after a negotiated milestone. It may also impose conditions tied to later patents, pediatric exclusivity, regulatory approval, or another product.

For investment and competitive analysis, Lupin’s actual entry position must be separated from:

• the termination date of the lawsuit;
• the end of the 30-month stay;
• expiration of the compound patent;
• expiration of method-of-use patents;
• FDA approval of Lupin’s ANDA; and
• any confidential settlement license.

The end of the litigation did not itself invalidate Boehringer’s patents or establish that Lupin could immediately commercialize a generic.

How strong was Boehringer’s Jardiance patent estate?

Boehringer’s estate was strongest before 2023 because the compound patent covered the active ingredient itself. That protection limited the practical value of label carving and made a fully substitutable generic difficult to market before compound-patent expiry.

The estate became more fragmented after compound-patent expiration:

Patent category	Strength against generic entry
Compound claims	High before expiration; low after expiration
Tablet or formulation claims	Depends on claim scope and generic design
Diabetes method claims	Moderate; vulnerable to label carve-outs and inducement defenses
Cardiovascular-use claims	Commercially important if the label includes the protected indication
Renal-use claims	Potentially significant for expanded Jardiance labeling
Manufacturing claims	Usually less effective against ordinary ANDA entry unless product manufacture practices the claims

The post-2023 risk profile depends on whether a generic launches with a full label, a carved-out label, or a label that omits later-protected indications.

What generic entry risks remained after the lawsuit?

The principal risks were later method-of-use patents, expanded Jardiance indications, and litigation over induced infringement. A generic could obtain approval for diabetes treatment while excluding a protected cardiovascular or renal indication, but the commercial value of that strategy depends on prescribing behavior and FDA labeling rules.

Manufacturing patents generally presented a secondary risk. They could matter if the generic used a protected process, but they were less likely than compound or method patents to block a standard tablet ANDA across the entire market.

The competitive market also included other ANDA applicants. A settlement with Lupin would not necessarily resolve separate cases involving Teva, Mylan, Zydus, Sun, or other generic manufacturers.

How does Jardiance compare with other SGLT2 inhibitors?

Product	Active ingredient	Sponsor	Primary patent risk profile
Jardiance	Empagliflozin	Boehringer Ingelheim	Compound patent expired in 2023; later-use patents remain relevant
Farxiga	Dapagliflozin	AstraZeneca	Compound and method patents with separate Orange Book history
Invokana	Canagliflozin	Janssen	Compound, formulation, and method-of-use disputes
Steglatro	Ertugliflozin	Merck/Pfizer	Smaller commercial base and separate patent estate

Jardiance has significant commercial exposure because the product expanded from diabetes treatment into cardiovascular and renal-risk reduction. That expansion increased the importance of later method-of-use patents after the original empagliflozin compound patent expired.

Key Takeaways

• Case No. 1:18-cv-01690 was a Hatch-Waxman dispute over Lupin’s ANDA for generic Jardiance, or empagliflozin.
• Boehringer relied on patent rights covering empagliflozin and its therapeutic use.
• The principal empagliflozin compound patent expired in 2023.
• Method-of-use and expanded-indication patents created later launch risks.
• The case ended without a reported public merits judgment.
• Settlement terms and any Lupin-specific launch date were not publicly disclosed.
• The lawsuit did not invalidate the Jardiance patent estate or determine the rights of unrelated generic applicants.
• Post-expiration competition depends on FDA approval, patent-use codes, label carving, later patents, and any confidential license terms.

FAQs

Was Boehringer v. Lupin a patent case involving Jardiance or Tradjenta?

It was a Jardiance-related ANDA patent dispute involving empagliflozin. Tradjenta contains linagliptin and is covered by a separate Boehringer patent and regulatory history.

Did Lupin win the Jardiance patent case?

There was no reported public merits judgment declaring the asserted patents invalid or noninfringed. The action ended without a publicly reported trial outcome.

Can a generic launch after the Jardiance compound patent expires?

Yes, subject to FDA approval and any surviving Orange Book-listed patents. Later method-of-use patents can still restrict a full-label launch or create induced-infringement risk.

Does a Paragraph IV settlement mean the patent is valid?

No. A settlement does not adjudicate validity, infringement, or enforceability unless the agreement includes a judgment or stipulated finding. Confidential settlement terms cannot be inferred from docket closure.

What is the main remaining patent risk for generic empagliflozin?

The main risk is post-compound method-of-use protection, particularly patents tied to cardiovascular or renal indications and any label that encourages use for a patented indication.

References

1. Boehringer Ingelheim Pharmaceuticals, Inc. v. Lupin Ltd., No. 1:18-cv-01690, U.S. District Court for the District of Delaware, docket materials.

2. Boehringer Ingelheim Pharmaceuticals, Inc., Complaint for Patent Infringement under the Hatch-Waxman Act, No. 1:18-cv-01690, U.S. District Court for the District of Delaware.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Jardiance, empagliflozin. FDA Orange Book.

4. U.S. Food and Drug Administration. (2024). Small business assistance: Frequently asked questions on the ANDA process. FDA.